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Gastric Cancer Studies Focus on Prolonging Survival
(Continued from page 1)

Localized cancer
The five-year overall survival rates
for patients with localized gastric cancer
are daunting: 78% for patients with
stage Ia cancer, 58% for stage Ib, 34%
for stage II, 20% for stage IIIa, and 8%
for stage IIIb. Currently, the only known
curative therapy for nonmetastatic
gastric cancer is a gastrectomy performed by experienced surgeons.
However, even with successful surgery,
the five-year survival rate is approximately 35%; with adjuvant chemoradiotherapy in selected patients, the
survival rate is 40%.
To improve survival rates in patients
with localized gastric cancer, clinicians
and researchers at The University of
Texas M. D. Anderson Cancer Center
have developed a strategy for treating
select patients with preoperative
therapy, a practice that is still investigational, cautioned Jaffer Ajani, M.D., a
professor in the Department of Gastrointestinal Medical Oncology. In an
ongoing clinical trial at M. D. Anderson, patients with operable gastric
cancer are receiving chemotherapy
followed by chemoradiotherapy followed by surgery.
According to Dr. Ajani, patients with
operable gastric cancer tolerate therapy
better before the stomach has been
removed. Furthermore, preoperative
therapy likely increases the chances of a
successful surgery, and several studies
have shown that a response to preoperative therapy is a powerful predictor of
survival. “One thing we know for sure is
that good surgery is an important factor
for cure,” Dr. Ajani said. “One approach
is to reduce the size of the cancer before
surgery. If you can reduce the stage before
surgery, that patient’s cancer is going to
behave as if it were [always] at an earlier
stage, and this could mean an advantage
for the patient.”
The results of a multi-institutional
study of preoperative chemoradiotherapy, which was led by Dr. Ajani,
were presented at the 1998 annual
meeting of the American Society of
Clinical Oncology and will soon be
published. A significant number of
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“Gastric cancers are
relatively aggressive
tumors. Although they
respond to treatment,
they quickly become
resistant to treatment.”
– James Yao, M.D.,
assistant professor,
Department of Gastrointestinal
Medical Oncology
patients—approximately 30%—had had
a complete pathologic response by the
time of surgery. However, only phase III
trials will determine the value of the
preoperative approach for patients with
localized gastric cancer, said Dr. Ajani.
Metastatic disease
The five-year survival rate for
patients with metastatic, stage IV gastric
cancer is 7% or less. Because most
metastatic gastric cancers are inoperable, they are treated with combination
chemotherapy. “This is one disease
where response to chemotherapy doesn’t
always translate into improvement in
survival,” said James Yao, M.D., an
assistant professor in the Department
of Gastrointestinal Medical Oncology.
“Gastric cancers are relatively aggressive
tumors. Although they respond to
treatment, they quickly become resistant
to treatment.”
New research initiatives and more
effective therapies are clearly needed for
patients with metastatic gastric cancer.
In the largest clinical trial ever completed in patients with advanced gastric
cancer, the interim results of which
were presented at the 2003 annual
meeting of the American Society of
Clinical Oncology, Dr. Ajani led
researchers from 14 nations in studying
the addition of docetaxel to 5-fluorouracil (5-FU) and cisplatin, which is the
most commonly used regimen. In this
phase III trial of 223 patients, adding
docetaxel caused more tumors to shrink,
delayed tumor growth, and prolonged

survival. This is the first study in which
more than 50% of patients with latestage gastric cancer lived for almost one
year (10.2 months or longer), compared
with a median survival duration of 8.5
months for patients receiving the
control regimen.
Dr. Ajani is also investigating the
efficacy of S-1 (a prodrug of 5-FU that
contains a compound that prevents the
breakdown of 5-FU) combined with
cisplatin in phase II trials of patients
with advanced gastric cancer. This
combination has been tested in Japan,
where the response rates were as high
as 70% but the effects on survival
were limited.
The key to prolonging survival with
chemotherapy, according to Dr. Ajani,
lies in increasing the time to tumor
progression: “The longer that time to
progression, the longer the patient is
going to live.”
To prolong the time to tumor
progression in patients with gastric
cancer, Dr. Ajani proposes that
oncologists change the treatment agent
the moment they know that maximum
response has occurred rather than
continuing treatment once the cancer
has started to progress. “That is the
period where you’re treating unnecessarily,” he explained. “Essentially, the
cancer is growing, and you’re giving
the same treatment that may be harming the patient. So, we would like to
[achieve the maximum response with
chemotherapy and then] bring in
another [nonchemotherapy] treatment,
something very simple that is not going
to lower the patient’s quality of life.”
Molecular biology and
translational research
At M. D. Anderson, a number
of people from a variety of disciplines
are coordinating translational and
molecular research efforts to discover
new targets for therapy and to understand the mechanisms of resistance to
chemotherapy and radiotherapy. “To
make an impact, we probably need to go
beyond the chemotherapy paradigm and
incorporate newer treatment strategies,

In his research of Sp1, a transcription factor that is overactivated in human gastric
cancers, Dr. Keping Xie, an associate professor in the departments of Gastrointestinal
Medical Oncology and Cancer Biology, and his research group are using small inhibitory
molecules and genetically engineering a gene similar to Sp1 to compete with Sp1 and block
it from binding with DNA and activating gene expression.
molecular and targeted treatments,”
Dr. Yao said.
One approach is to add targeted
biologic therapy to chemotherapy and
chemoradiotherapy. “Targeted agents
may selectively increase the response
to chemoradiation, which is important
since many of the combinations of
chemotherapy and radiotherapy in past
gastric cancer studies have had significant gastrointestinal side effects,” said
Christopher Crane, M.D., an associate
professor in the Department of Radiation Oncology. According to Dr. Crane,
future studies will include targeted
agents with chemoradiation based
on preliminary work done at M. D.
Anderson in pancreatic cancer.
Using a tumor database developed
from almost 3,000 patients’ tissue
samples, Dr. Yao and other researchers
at M. D. Anderson are looking for
molecular markers of gastric cancer that
could be targeted in therapy and trying
to correlate them with patient outcome
and survival. These markers include
tumor suppressor genes p53 and fragile

histidine triad, the adhesion molecules
E-cadherin and cluster of differentiation
44, the tyrosine kinases epidermal
growth factor receptor and plateletderived growth factor, and vascular
endothelial growth factor (VEGF),
which plays an important role in
angiogenesis.
Keping Xie, M.D., Ph.D., an associate
professor in the departments of Gastrointestinal Medical Oncology and
Cancer Biology, was recently awarded
a five-year grant from the American
Cancer Society to study molecular
markers for gastric cancer. “If certain
molecular markers can consistently
predict a patient’s outcome,” explained
Dr. Xie, “we can better understand
gastric cancer development and
progression and design more effective
strategies to block or reverse its
malignant phenotype.”
Based on his previous research with
pancreatic cancer, Dr. Xie is focusing on
a transcription factor called Sp1. Sp1 is
overactivated in human gastric cancers,
and abnormal Sp1 activation has been

linked with the overexpression of
many genes downstream of Sp1 that are
involved in aggressive tumor behavior.
For example, Sp1 controls the
expression of VEGF. Using human
gastric cancer specimens, Dr. Xie and
colleagues at M. D. Anderson investigated the expression level of Sp1
and its relationship to VEGF and
microvessel density, or the angiogenic
phenotype. They found that elevated
Sp1 expression and the related overexpression of VEGF were directly
associated with microvessel density
and predicted a poor outcome for the
patient. The results of their study were
published in Clinical Cancer Research
in December 2003.
Dr. Xie and his research group are
also investigating Sp1’s relationship
to other prognostic markers, including
genes related to metastasis, apoptosis
resistance, and proliferation, as well as
other factors involved in angiogenesis.
“Sp1 is much, much better than the
molecules we have looked at so far in
predicting patients’ outcomes. Because
this molecule is pivotal in controlling
many aspects of cancer biology, it can
be a consistent tumor marker as well as
a very good target for therapy. [Through
Sp1], you can trap the tumor quite easily
and control tumor growth and eventually metastasis,” Dr. Xie said.
Future directions
According to Dr. Ajani, gastric
cancer should be investigated from all
angles. By joining efforts, gastroenterologists, pathologists, medical oncologists,
radiation oncologists, and surgical
oncologists can improve the clinical
outcomes of patients with gastric cancer.
At the same time, the discoveries made
by molecular biologists, molecular
pathologists, gastrointestinal biologists,
and molecular epidemiologists are
helping to overcome the challenges
posed by gastric carcinoma. ●
FOR MORE INFORMATION, contact
Dr. Ajani, Dr. Yao, or Dr. Xie at
(713) 792-2828 or Dr. Crane at
(713) 563-2340.
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Clinical Ethicists Help Patients, Families,
and Staff Resolve Difficult Dilemmas
by Karen Stuyck

A

patient lies in the
intensive-care unit,
in critical condition
and unable to communicate. He has no living
will and no family member or
friend with medical power of
attorney to make health-care
decisions for him. Who, then,
decides whether life-sustaining
measures such as ventilation or
nutritional support are started?
Who decides at what point these
measures should be stopped?

Another patient refuses treatment
that her doctors agree would be medically
beneficial. What recourse do her physicians and family members have? What
if the patient doesn’t understand what
the health professionals are telling her?
Fortunately, there are professionals
available at many hospitals to help
resolve these and other dilemmas.
At The University of Texas M. D.
Anderson Cancer Center, the Clinical
Ethics Service conducts about 100 ethics
consultations a year, according to Martin
L. Smith, S.T.D., chief of the service.
About 95% of the consultation requests
come from M. D. Anderson health
professionals, with the rest requested
by patients and their families.
More than half of these consultations, Dr. Smith said, center around endof-life issues, such as whether to stop or
start life support, including whether to
put a patient on a ventilator, start
dialysis, or initiate resuscitation. About
30% of the Clinical Ethics Service’s
consultations involve patients in the
intensive-care unit. Often “in the
intensive-care unit, there is a critically
ill patient with multiorgan failure, for
example, and the health-care professionals are questioning how aggressive they
should be,” Dr. Smith said.
4
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Clinical ethicists
at M. D. Anderson help
identify, analyze, and
resolve ethical issues by
gathering information
and discussing the
problem with the
involved health
professionals, the
patient, and the family.
The ethicists offer
advice, make recommendations, and help
identify options, but
they don’t make
decisions for the
persons involved.
Making sure that
those involved have a
common understanding
of the issue is a big part
of these consultations,
Dr. Smith said. He
related one case in
which an ethicist was
asked to help determine
who should make
decisions for a heavily
sedated patient in
intensive care who had left no written
instructions. The patient had told his
physician earlier that he did not want his
wife to make any medical decisions for
him because he was planning to divorce
her once he recovered. Now the patient
was unable to communicate his wishes.
Was he serious about his intentions? If so,
who instead should make the decisions?
The ethicist talked to some of the
staff members involved with the patient,
and a nurse suggested decreasing the
patient’s medication so that they could
have a conversation with him. The
ethicist supported the nurse’s recommendation. When the patient’s level
of sedation was reduced, the nurse and
a social worker spoke to him, and he
said that he wanted his wife to be the
decision maker.
About 85% of the ethics consultations are conducted by one ethicist, Dr.
Smith said, but sometimes “very significant conflicts or tough dilemmas” require

The members of the Clinical Ethics Service
—Dr. Martin L. Smith (left, background), chief; Anne L. Flamm (center,
background), a clinical ethicist; and Dr.
Barbara J. Evans (right, background), a
clinical ethics fellow, consult with Vanessa
L. Davis, a clinical nurse in the Symptom
Control and Palliative Care Center.
the services of a four-person Clinical
Ethics Consult Team. In addition to an
ethicist, this team consists of an M. D.
Anderson physician, a nurse, and an
“ancillary other,” such as an allied health
professional, or a social worker, chaplain,
or patient advocate, none of whom is
involved in the patient’s care. The
physician, nurse, and ancillary other are
always members of M. D. Anderson’s
Clinical Ethics Committee. More than
half of these difficult cases concern endof-life issues. “A frequent theme is that
a patient, in the judgment of the healthcare team, is dying, but the family

Male Breast Cancer
(Continued from page 5)
October 2002, she reviewed 114 articles
published between 1942 and 2000. In
a report accepted for publication in
Cancer, she analyzed data from 1973 to
1998 in the National Cancer Institute’s
Surveillance, Epidemiology, and End
Results database, a cancer registry that
includes data from 14% of the U.S.
population. In this study, 2,524 cases of
male breast cancer were compared with
380,856 cases of female breast cancer.
“Most men do not even think they
can get breast cancer,” said Dr. Giordano.
Mr.
speculates that many men
ignore the signs and delay the doctor
visit because they are embarrassed or in
denial. Because of his quick action in
going to the doctor (and scheduling his
mastectomy for the first day available—
a Friday the 13th),
cancer
was stage I when it was removed.
When men do seek medical attention for their symptoms, 85% of the
time they report a painless subareolar
mass. Often, this is mistakenly diagnosed as gynecomastia, a benign
swelling of the breast tissue that up
to a third of men experience in their
lifetimes. Other symptoms at presentation include local pain and nipple
ulceration, retraction, bleeding, or
discharge. In men, the cancer tends
to involve the nipple, the skin, and
the muscles because there is less breast
tissue to invade.
A family history of breast cancer
appears to be a risk factor for men: 15%
to 20% of men with breast cancer have
a family history, compared with 7% of
the general male population. Carrying
the BRCA1 gene mutation does not
seem to increase risk in men, but the
BRCA2 gene defect confers significant
risk. Many risk factors are related to
abnormalities in estrogen and androgen
balance; other risk factors include
testicular defects or injury, infertility,
Klinefelter syndrome, obesity, cirrhosis,
benign breast conditions or breast
trauma, increasing age, Jewish ancestry,
and radiation and estrogen exposure.
Ironically, breast cancers in men
are more likely to be estrogen receptor
positive and progesterone receptor
positive than those in women. “It’s
counterintuitive because estrogen and
6
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“Most men
do not even think
they can get
breast cancer.”
– Sharon Giordano, M.D., M.P.H.,
assistant professor, Department of
Breast Medical Oncology

progesterone are female hormones,”
said Dr. Giordano. Most men’s breast
tumors (90%) are invasive, and the
predominant histologic subtype is
infiltrating ductal carcinoma (80%).
Dr. Giordano is very interested in
how breast cancers in men differ
biologically from those in women.
The literature review she published in
2002 showed that breast cancers in
men and women express many of the
same molecular markers—c-erbB-2,
p53, cyclin D1, and epidermal growth
factor receptor—to the same degrees.
However, men may have higher rates
of Bcl-2 overexpression.
Five- and 10-year disease-specific
survival rates are similar in men and
women, but the overall survival rate is
lower in men. As with women, lymph
node status, tumor size, histologic grade,
and hormone receptor status are
significant prognostic factors for men.
Because no large, population-based
studies have been conducted, many of
these findings have not been verified.
Furthermore, no large clinical trials
have studied breast cancer treatment for
men; most men are treated based on the
standard of care guidelines established
for women, which often indicate a
modified radical mastectomy, axillary
lymph node biopsy, and adjuvant
therapy. The high rates of hormone
receptor–positive tumors in male breast
cancer suggest that adjuvant hormonal
therapy could be effective, and indeed,
the recommendation for men with
hormone receptor–positive tumors is
daily tamoxifen for five years.
Mr.
whose cancer was estrogen
receptor positive, had great reservations
about taking tamoxifen because of the
increased risk of blood clots and stroke.
“All of the hormonal questions, the

possible impact on sexual activity,
none of those things bothered me
because I knew that men produce
estrogen. The only thing that bothered
me was the fact that I didn’t want to be
cured of breast cancer and die from a
stroke or blood clot,” said Mr.
who decided after much inner debate
to take the pills.
While Mr.
initially had no
side effects, he later began experiencing
gastrointestinal and vision problems,
adverse effects that have been reported
by other patients. After six months
of taking tamoxifen, he decided to
discontinue its use and since then has
been feeling much better.
Dr. Giordano is very interested in
studying how hormonal therapies may
affect men differently. She plans to set
up a registry with a standardized treatment algorithm for men, looking at
outcomes and toxicity and correlating
side effects with prognosis. She also
intends to build a tissue bank of breast
tumors from men.
In addition to the lack of research or
data, the greatest problem for men with
breast cancer may be the stigma associated with having what is traditionally
considered a woman’s disease.
“I am sure there is a psychological
burden to it, just because a lot of breast
cancer centers are called women’s
centers. Everyone assumes that they
are a woman,” said Dr. Giordano. “It is
important to keep the public consciousness open. People should be aware that
[breast cancer] can happen [to men].”
According to Mr.
preconceived ideas about what a man is are
a problem for all men seeking medical
care. “Real men don’t cry. Real men
don’t show pain. It is ludicrous because
those real men die,” said Mr.
“The [breast cancer] death rate among
men is so high because most men ignore
it and don’t do anything about it, and
by the time they do anything about it,
it is in an advanced stage. I can tell
other people, and if they can discover
it as early as I did or earlier, then lives
can be saved.” ●
FOR MORE INFORMATION, contact
Dr. Giordano at (713) 792-2817.

